{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:10:23Z","timestamp":1787505023533,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902580"],"award-info":[{"award-number":["81902580"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>DDX41<\/jats:italic>\n                    is one of the most frequently altered genes in familial acute myeloid leukemia\/myelodysplastic syndrome (AML\/MDS). Mutation of\n                    <jats:italic>DDX41<\/jats:italic>\n                    has been widely reported in various types of myeloid neoplasms. This systematic review and meta-analysis were conducted to assess the clinical characteristics and relationship between\n                    <jats:italic>DDX41<\/jats:italic>\n                    mutations and OS in myeloid neoplasm patients. We thoroughly searched the PubMed, the Cochrane Library, Embase, Web of Science, MEDLINE, and Google Scholar databases. Two reviewers separately reviewed and extracted the data. Twenty studies totaling 9,058 patients have been integrated into the meta-analysis. The extensive pooled analysis showed a significant association between\n                    <jats:italic>DDX41<\/jats:italic>\n                    mutations and improved OS (HR 0.70, 95% CI 0.52\u20130.93,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01). Subgroup analysis confirmed that\n                    <jats:italic>DDX41<\/jats:italic>\n                    mutation operated to be a reliable positive indicator of OS when subdivided by different types of myeloid neoplasms. In terms of the clinicopathological value,\n                    <jats:italic>DDX41<\/jats:italic>\n                    mutations were significantly correlated with the male sex and older age. AML prevalence, bone marrow, or white blood cell counts did not correlate with any findings. The top three genetic variants were p.M1I, p.D140fs, and p.R525H. Co-mutations in patients with DDX41 mutations most commonly include the following: additional sex combs-like 1 (\n                    <jats:italic>ASXL1<\/jats:italic>\n                    ), DNA methyltransferase 3\u00a0A (\n                    <jats:italic>DNMT3A<\/jats:italic>\n                    ), tumor protein p53 (\n                    <jats:italic>TP53<\/jats:italic>\n                    ), ten-eleven translocation 2 (\n                    <jats:italic>TET2<\/jats:italic>\n                    ) and serine\/arginine-rich splicing factor 2 (\n                    <jats:italic>SRSF2<\/jats:italic>\n                    ). Our results substantiate that\n                    <jats:italic>DDX41<\/jats:italic>\n                    mutations were associated with significantly good OS and provide more insight into the clinicopathological characteristics of\n                    <jats:italic>DDX41<\/jats:italic>\n                    mutations in individuals with myeloid neoplasms.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06278-1","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:31:34Z","timestamp":1745195494000},"page":"2581-2591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Liying","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"6278_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/biom12020291","volume":"12","author":"DG Torres","year":"2022","unstructured":"Torres DG, Paes J, da Costa AG, Malheiro A, Silva GV, Mour\u00e3o LPS et al (2022) JAK2 variant signaling: genetic, hematologic and immune implication in chronic myeloproliferative neoplasms. Biomolecules 12:291","journal-title":"Biomolecules"},{"key":"6278_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.26751","volume":"98","author":"J Thiele","year":"2023","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM et al (2023) The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms. Am J Hematol 98:166\u2013179","journal-title":"Am J Hematol"},{"key":"6278_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-021-01068-4","volume":"14","author":"M Simonin","year":"2021","unstructured":"Simonin M, Schmidt A, Bontoux C, Dourthe M, Lenglin\u00e9 E, Andrieu G et al (2021) Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. J Hematol Oncol 14:74","journal-title":"J Hematol Oncol"},{"key":"6278_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13238-016-0351-9","volume":"8","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Zhu Y, Qiu W, Liu Y-J, Cheng G, Liu Z-J et al (2016) Structural and functional analyses of human DDX41 DEAD domain. Protein Cell 8:72\u201376","journal-title":"Protein Cell"},{"key":"6278_CR5","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/s41375-022-01708-9","volume":"36","author":"S Shinriki","year":"2022","unstructured":"Shinriki S, Hirayama M, Nagamachi A, Yokoyama A, Kawamura T, Kanai A et al (2022) DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells. Leukemia 36:2605\u20132620","journal-title":"Leukemia"},{"key":"6278_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N et al (2015) Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 27:658\u2013670","journal-title":"Cancer Cell"},{"key":"6278_CR7","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood.2019000909","volume":"134","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, Passet M, Raimbault A, Rahm\u00e9 R, Raffoux E, Sicre de Fontbrune F et al (2019) Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood 134:1441\u20131444","journal-title":"Blood"},{"key":"6278_CR8","doi-asserted-by":"crossref","unstructured":"Makishima H, Saiki R, Nannya Y et al (2023) Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. BloodBlood 141(5):534\u2013549","DOI":"10.1182\/blood.2022018221"},{"key":"6278_CR9","doi-asserted-by":"crossref","unstructured":"Fei Y, Nicola L, Tauangtham A, Daniel B, Jonathan CS, Tiffany L et al (2021) Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood 139:1208\u20131221","DOI":"10.1182\/blood.2021011354"},{"key":"6278_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"key":"6278_CR11","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"6278_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"6278_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ajh.25486","volume":"94","author":"AE Quesada","year":"2019","unstructured":"Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD et al (2019) DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 94:757\u2013766","journal-title":"Am J Hematol"},{"key":"6278_CR14","doi-asserted-by":"publisher","first-page":"582213","DOI":"10.3389\/fonc.2020.582213","volume":"10","author":"SA Bannon","year":"2020","unstructured":"Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K et al (2020) Next-Generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Front Oncol 10:582213","journal-title":"Front Oncol"},{"key":"6278_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/bjh.16668","volume":"192","author":"S Qu","year":"2021","unstructured":"Qu S, Li B, Qin T, Xu Z, Pan L, Hu N et al (2021) Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations. Br J Haematol 192:1006\u20131010","journal-title":"Br J Haematol"},{"key":"6278_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/jha2.256","volume":"2","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang F, Chen X, Liu H, Wang X, Chen J et al (2021) Next-generation sequencing reveals the presence of DDX41 mutations in acute lymphoblastic leukemia and aplastic anemia. EJHaem 2:508\u2013513","journal-title":"EJHaem"},{"key":"6278_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1182\/bloodadvances.2021005738","volume":"6","author":"HB Alkhateeb","year":"2022","unstructured":"Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L et al (2022) Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv 6:528\u2013532","journal-title":"Blood Adv"},{"key":"6278_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3324\/haematol.2020.270553","volume":"107","author":"EJ Choi","year":"2022","unstructured":"Choi EJ, Cho YU, Hur EH, Jang S, Kim N, Park HS et al (2022) Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica 107:510\u2013518","journal-title":"Haematologica"},{"key":"6278_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1182\/blood.2021015135","volume":"140","author":"P Li","year":"2022","unstructured":"Li P, Brown S, Williams M, White T, Xie W, Cui W et al (2022) The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood 140:716\u2013755","journal-title":"Blood"},{"key":"6278_CR20","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3324\/haematol.2023.282867","volume":"108","author":"T Badar","year":"2023","unstructured":"Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T et al (2023) Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. Haematologica 108:3033\u20133043","journal-title":"Haematologica"},{"key":"6278_CR21","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/ajh.27070","volume":"98","author":"A Bataller","year":"2023","unstructured":"Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS et al (2023) Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98:1780\u20131790","journal-title":"Am J Hematol"},{"key":"6278_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2022018221","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J et al (2023) Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood 141:534\u2013549","journal-title":"Blood"},{"key":"6278_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/ajcp\/aqab027","volume":"156","author":"T Goyal","year":"2021","unstructured":"Goyal T, Tu ZJ, Wang Z, Cook JR (2021) Clinical and pathologic spectrum of DDX41-Mutated hematolymphoid neoplasms. Am J Clin Pathol 156:829\u2013838","journal-title":"Am J Clin Pathol"},{"key":"6278_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41375-021-01404-0","volume":"36","author":"P Li","year":"2022","unstructured":"Li P, White T, Xie W, Cui W, Peker D, Zeng G et al (2022) AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia 36:664\u2013674","journal-title":"Leukemia"},{"key":"6278_CR25","doi-asserted-by":"publisher","first-page":"1153082","DOI":"10.3389\/fonc.2023.1153082","volume":"13","author":"A Tierens","year":"2023","unstructured":"Tierens A, Kagotho E, Shinriki S, Seto A, Smith AC, Care M et al (2023) Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia. Front Oncol 13:1153082","journal-title":"Front Oncol"},{"key":"6278_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12185-019-02770-3","volume":"111","author":"C Polprasert","year":"2020","unstructured":"Polprasert C, Takeda J, Niparuck P, Rattanathammethee T, Pirunsarn A, Suksusut A et al (2020) Novel DDX41 variants in Thai patients with myeloid neoplasms. Int J Hematol 111:241\u2013246","journal-title":"Int J Hematol"},{"key":"6278_CR27","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1038\/s41375-021-01246-w","volume":"35","author":"D Singhal","year":"2021","unstructured":"Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM et al (2021) Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia 35:3245\u20133256","journal-title":"Leukemia"},{"key":"6278_CR28","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1182\/bloodadvances.2023009742","volume":"7","author":"F Guijarro","year":"2023","unstructured":"Guijarro F, L\u00f3pez-Guerra M, Morata J, Bataller A, Paz S, Cornet-Masana JM et al (2023) Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome. Blood Adv 7:5799\u20135811","journal-title":"Blood Adv"},{"key":"6278_CR29","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","volume":"37","author":"E Jahn","year":"2023","unstructured":"Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L et al (2023) Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 37:2187\u20132196","journal-title":"Leukemia"},{"key":"6278_CR30","doi-asserted-by":"publisher","first-page":"7346","DOI":"10.1182\/bloodadvances.2023011389","volume":"7","author":"A Maierhofer","year":"2023","unstructured":"Maierhofer A, Mehta N, Chisholm RA, Hutter S, Baer C, Nadarajah N et al (2023) The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing. Blood Adv 7:7346\u20137357","journal-title":"Blood Adv"},{"key":"6278_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41580-023-00628-5","volume":"24","author":"KE Bohnsack","year":"2023","unstructured":"Bohnsack KE, Yi S, Venus S, Jankowsky E, Bohnsack MT (2023) Cellular functions of eukaryotic RNA helicases and their links to human diseases. Nat Rev Mol Cell Biol 24:749\u2013769","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6278_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-biochem-032620-105429","volume":"91","author":"K Weis","year":"2022","unstructured":"Weis K, Hondele M (2022) The role of DEAD-box ATPases in gene expression and the regulation of RNA\u2013protein condensates. Annu Rev Biochem 91:197\u2013219","journal-title":"Annu Rev Biochem"},{"key":"6278_CR33","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1182\/blood-2010-08-303479","volume":"117","author":"F Damm","year":"2011","unstructured":"Damm F, Heuser M, Morgan M, Wagner K, G\u00f6rlich K, Gro\u00dfhennig A et al (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561\u20134568","journal-title":"Blood"},{"key":"6278_CR34","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41375-022-01561-w","volume":"36","author":"F Nguyen-Khac","year":"2022","unstructured":"Nguyen-Khac F, Bidet A, Daudignon A, Lafage-Pochitaloff M, Ameye G, Bilhou-Nab\u00e9ra C et al (2022) The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone group of hematological cytogenetics (GFCH). Leukemia 36:1451\u20131466","journal-title":"Leukemia"},{"key":"6278_CR35","doi-asserted-by":"crossref","unstructured":"Kadono M, Kanai A, Nagamachi A, Shinriki S, Kawata J, Iwato K et al (2016) Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia. Exp Hematol.; 44: 745\u2013\u200954.e4.","DOI":"10.1016\/j.exphem.2016.04.017"},{"key":"6278_CR36","doi-asserted-by":"publisher","first-page":"1451705","DOI":"10.3389\/fimmu.2024.1451705","volume":"15","author":"J Ma","year":"2024","unstructured":"Ma J, Ross SR (2024) Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease. Front Immunol 15:1451705","journal-title":"Front Immunol"},{"key":"6278_CR37","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.stem.2021.08.004","volume":"28","author":"TM Chlon","year":"2021","unstructured":"Chlon TM, Stepanchick E, Hershberger CE, Daniels NJ, Hueneman KM, Davis AK et al (2021) Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell 28:1966\u20131981e6","journal-title":"Cell Stem Cell"},{"key":"6278_CR38","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2020.257246","volume":"107","author":"JT Weinreb","year":"2022","unstructured":"Weinreb JT, Gupta V, Sharvit E, Weil R, Bowman TV (2022) Ddx41 Inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish. Haematologica 107:644","journal-title":"Haematologica"}],"updated-by":[{"DOI":"10.1007\/s00277-026-06822-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06278-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:03:20Z","timestamp":1770177800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06278-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6278"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06278-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-026-06822-7","URL":"https:\/\/doi.org\/10.1007\/s00277-026-06822-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}